-
1 Comment
Betta Pharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 10.1% below its 200 day moving average.
From a valuation standpoint, the stock is 133.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 22.5.
Betta Pharmaceuticals Co., Ltd's total revenue rose by 16.8% to $363M since the same quarter in the previous year.
Its net income has increased by 186.7% to $93M since the same quarter in the previous year.
Finally, its free cash flow fell by 68.0% to $8M since the same quarter in the previous year.
Based on the above factors, Betta Pharmaceuticals Co., Ltd gets an overall score of 2/5.
| ISIN | CNE100002DD9 |
|---|---|
| Exchange | SHE |
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 20B |
|---|---|
| Target Price | 64.54 |
| Dividend Yield | 0.3% |
| Beta | 0.66 |
| PE Ratio | 50.29 |
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is headquartered in Hangzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300558.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
